To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Viatris Inc. (VTRS) recently reported a fourth quarter that fell short of Wall Street expectations, missing revenue and ...

Syria's Islamist-led government on Monday said it had completed a military operation against a nascent insurgency by Bashar ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

President Donald Trump has proposed a U.S. takeover of Gaza while also suggesting a permanent displacement of Palestinians ...

A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against the U.S. Food and Drug Administration (FDA). This time, ...

Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s drug semaglutide is no longer in shortage in the U.S.

These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Intra-Cellular ...

Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...